利用表观遗传点来克服前列腺癌中对标素的抗性
Buse Cevatemre1, Ipek Bulut2, Beyza Dedeoglu3
1Koc University Research Center for Translational Medicine, Istanbul, Turkey.
Cell death & disease
|February 12, 2024
概括
基因和RING指域含有蛋白质 (BRPF) 的抑制通过向ABCB1流动,使得割抵抗性前列腺癌 (CR-PCa) 对分类基因重新敏感. 这种表观遗传策略恢复了药物易感性,并为抗性前列腺癌提供了新的治疗途径.
科学领域:
- 表观遗传学和癌症治疗方法
- 前列腺癌研究 研究前列腺癌
- 药物耐药性机制 药物耐药性机制
背景情况:
- 塔克桑耐药性是治疗抗割前列腺癌 (CR-PCa) 的重要障碍,限制了治疗疗效.
- 识别新的治疗点对于克服对象抗性和改善CR-PCa患者的治疗结果至关重要.
研究的目的:
- 为了确定新的表观遗传标,可以逆转CR-PCa.中的税种耐药性.
- 调查BRPF读者蛋白在ABCB1.1介导的分类物耐药性中的作用.
主要方法:
- 在对抗税的CR-PCa细胞进行了表观遗传药物选.
- 利用了BRPF抑制,细胞循环分析,细胞亡试验和药物抑制.
- 进行染色体免疫沉,然后进行定量PCR (ChIP-qPCR) 和RNA测序 (RNA-seq).
主要成果:
- 确定了BRPF读者蛋白作为关键标,可以逆转ABCB1介导的对标抗性.
- 抑制BRPF使抗性CR-PCa细胞重新敏感,导致G2/M细胞周期停止和细胞亡.
- 发现BRPF1直接调节ABCB1促进体,影响mTORC1和UPR信号通路.
结论:
- 准BRPF是一种有希望的策略,通过恢复药物敏感性来克服CR-PCa中的分类物耐药性.
- 在调节ABCB1和相关信号通路方面,BRPF1的作用为对税种抗性机制提供了新的见解.
- 结合抑制ABCB1和mTOR通路,以及针对BRPF,可能会增强抗性前列腺癌的治疗反应.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
